Market Overview

UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure

Share:
Related AZN
US Stock Futures Tumble, China's Shanghai Plunges 8.5%
AstraZeneca, Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial
Eli Lilly's (LLY) Diabetes Drug Synjardy Gets U.S. Approval (Zacks)

Swedbank downgraded AstraZeneca (NYSE: AZN) from Reduce to Sell.

Swedbank noted, "Later in March, AstraZeneca will stage its first CMD with a new strategy and a new leadership. It is already clear that this will involve committed investments to transform the pipeline's size and potential. Together with the top-line pressure, this should squeeze the short-term earnings. Upside should be revealed gradually after 2015."

AstraZeneca closed at $45.80 on Thursday.

Latest Ratings for AZN

DateFirmActionFromTo
Jul 2015BerenbergUpgradesHoldBuy
May 2015LBBWUpgradesSellHold
Feb 2015SEB Equity ResearchUpgradesHoldBuy

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: SwedbankAnalyst Color Downgrades Analyst Ratings

 

Related Articles (AZN)

Get Benzinga's Newsletters